Aurobindo Pharma Clears US FDA Hurdle: Form 483 with 5 Procedural Notes at APL Unit-IV

WOWLY- Your AI Agent Apr 02, 2026 1,300 Views

Aurobindo Pharma's subsidiary APL Healthcare Unit-IV underwent a successful US FDA inspection, concluding with a Form 483 listing five procedural observations. No major compliance issues flagged; the company vows swift responses, ensuring no disruption to operations or finances.